OTCMKTS:BIOVF Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Price, News & Analysis → Strange new buyer driving up gold (From Stansberry Research) (Ad) Free BIOVF Stock Alerts $22.87 -2.13 (-8.52%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$22.87▼$23.7450-Day Range$22.87▼$27.7952-Week Range$18.35▼$27.79Volume3,000 shsAverage Volume47 shsMarket CapitalizationN/AP/E Ratio31.76Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Swedish Orphan Biovitrum AB (publ) alerts: Email Address Ad Stansberry ResearchStrange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."But there's a much better move you can make to get in front of these big moves today. About Swedish Orphan Biovitrum AB (publ) Stock (OTCMKTS:BIOVF)Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.Read More BIOVF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIOVF Stock News HeadlinesApril 17, 2024 | americanbankingnews.comSwedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest UpdateApril 4, 2024 | prnewswire.comNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)April 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."April 2, 2024 | finance.yahoo.comSobi publishes Annual and sustainability report for 2023February 20, 2024 | au.finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (SWOBY)February 8, 2024 | finance.yahoo.comSobi publishes Q4 2023 report: Strong revenue performance and growth into 2024February 3, 2024 | realmoney.thestreet.comSwedish Orphan Biovitrum price target raised to SEK 385 at RBC CapitalFebruary 1, 2024 | finance.yahoo.comAll You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong BuyApril 19, 2024 | Stansberry Research (Ad)Strange new buyer driving up goldOne Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."January 24, 2024 | finance.yahoo.comInvitation: Sobi's Q4 and FY 2023 reportJanuary 5, 2024 | finance.yahoo.comSobi's Chairman of the Board resigns due to health reasonsNovember 30, 2023 | finance.yahoo.comChange in number of shares and votes in Swedish Orphan Biovitrum AB (publ)November 23, 2023 | morningstar.comSwedish Orphan Biovitrum AB BIOVFNovember 1, 2023 | finance.yahoo.comSobi has completed the issuances of series C sharesOctober 30, 2023 | msn.comSwedish Orphan Biovitrum AB Non-GAAP EPS of SEK0.54, revenue of SEK5.17BOctober 30, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss EstimatesOctober 30, 2023 | finance.yahoo.comSobi publishes Q3 2023 report: Strong revenue and solid performanceOctober 27, 2023 | finance.yahoo.comReminder: Invitation: Sobi's Q3 2023 reportOctober 18, 2023 | finance.yahoo.comInvitation: Sobi's Q3 2023 reportSeptember 15, 2023 | finance.yahoo.comReminder: Sobi KOL investor event: Advancing the standard of care in haemophiliaSeptember 8, 2023 | finance.yahoo.comSobi KOL investor event: Advancing the standard of care in haemophiliaAugust 29, 2023 | finance.yahoo.comIs Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?August 22, 2023 | finance.yahoo.comSobi resolves on a rights issue of approximately SEK 6,024 millionAugust 15, 2023 | finance.yahoo.comBulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)July 19, 2023 | tmcnet.comNotice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)July 18, 2023 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue EstimatesJuly 18, 2023 | prnewswire.comSobi publishes Q2 2023 report: Growth and pipeline expansionSee More Headlines Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CUSIPN/A CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,612Year Founded2001Profitability EPS (Most Recent Fiscal Year)$0.72 Trailing P/E Ratio31.76 Forward P/E RatioN/A P/E GrowthN/ANet Income$227.17 million Net Margins10.95% Pretax Margin13.35% Return on Equity8.93% Return on Assets3.98% Debt Debt-to-Equity Ratio0.34 Current Ratio0.66 Quick Ratio0.46 Sales & Book Value Annual Sales$2.09 billion Price / SalesN/A Cash Flow$1.74 per share Price / Cash Flow13.13 Book Value$10.82 per share Price / Book2.11Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.49 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Guido Oelkers (Age 59)CEO & President Comp: $22.78MMr. Henrik Stenqvist (Age 57)Chief Financial Officer Mr. Torbjörn Hallberg (Age 55)General Counsel & Head of Legal Affairs Mr. Daniel Rankin (Age 44)Head of Strategy & Corporate Development Ms. Lena Bjurner (Age 56)Head of Human Resources Mr. Armin Reininger M.D. (Age 67)Ph.D., Senior Scientific & Medical Advisor Mr. Norbert Oppitz (Age 57)Head of International Mr. Sofiane Fahmy (Age 52)Head of Europe Mr. Duane H. Barnes (Age 64)Head of North America Mr. Mahmood Ladha (Age 60)Head of Strategic Transformation Operations More ExecutivesKey CompetitorsMasimoNASDAQ:MASIAmplifonOTCMKTS:AMFPFRamsay Health CareOTCMKTS:RMYHYViking TherapeuticsNASDAQ:VKTXCerevel TherapeuticsNASDAQ:CEREView All Competitors BIOVF Stock Analysis - Frequently Asked Questions Should I buy or sell Swedish Orphan Biovitrum AB (publ) stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Swedish Orphan Biovitrum AB (publ) in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOVF shares. View BIOVF analyst ratings or view top-rated stocks. How have BIOVF shares performed in 2024? Swedish Orphan Biovitrum AB (publ)'s stock was trading at $26.25 on January 1st, 2024. Since then, BIOVF stock has decreased by 12.9% and is now trading at $22.87. View the best growth stocks for 2024 here. Are investors shorting Swedish Orphan Biovitrum AB (publ)? Swedish Orphan Biovitrum AB (publ) saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 734,400 shares, an increase of 9.8% from the March 15th total of 669,100 shares. Based on an average trading volume of 200 shares, the short-interest ratio is currently 3,672.0 days. View Swedish Orphan Biovitrum AB (publ)'s Short Interest. How were Swedish Orphan Biovitrum AB (publ)'s earnings last quarter? Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) posted its quarterly earnings results on Thursday, February, 8th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.56 by $0.26. The firm earned $643.39 million during the quarter, compared to analysts' expectations of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a trailing twelve-month return on equity of 8.93% and a net margin of 10.95%. How do I buy shares of Swedish Orphan Biovitrum AB (publ)? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIOVF) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm PressHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.